Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gridelli, C, Frontini, L, Perrone, F, Gallo, C, Gulisano, M, Cigolari, S, Castiglione, F, Robbiati, S F, Gasparini, G, Ianniello, G P, Farris, A, Locatelli, M C, Felletti, R, Piazza, E
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2000
Teme:
Regular Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki